Neurocrine Biosciences Inc vs Symbotic Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Symbotic Inc trades at $43.07 (market cap $5.19B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.4× Symbotic Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SYM | |
|---|---|---|
Market Cap | $17.40B | $5.19B |
Sector | Health | Technology |
52-Week High | $180.55 | $87.30 |
52-Week Low | $123.10 | $38.57 |
Enterprise Value | $16.49B | $3.18B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →